Quizartinib (Vanflyta)
Jump to navigation
Jump to search
Mechanism of action
FLT3 inhibitor
Toxicity management
Diseases for which it is established
History of changes in FDA indication
- 2023-07-20: Approved with standard cytarabine and anthracycline induction for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (Based on QuANTUM-First)
- 2023-07-20: Approved with cytarabine consolidation for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (Based on QuANTUM-First)
- 2023-07-20: Approved as maintenance monotherapy following consolidation chemotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive, as detected by an FDA-approved test. (Based on QuANTUM-First)
History of changes in PMDA indication
- 2019-06-18: Newly indicated for the treatment of relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia.
Also known as
- Code names: AC-220, ASP-2689
- Brand name: Vanflyta